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INDUCTION OF LIVER ABCG5/ABCG8 EXPRESSION IS AN IMPORTANT
DETERMINANT OF THE MACROPHAGE-TO-FECES REVERSE CHOLESTEROL
TRANSPORT RESPONSE TO TREATMENT WITH EZETIMIBE
JESSICA B. ALTEMUS

ABSTRACT
Reverse cholesterol transport (RCT) consists of the transfer of cholesterol from
peripheral tissues for excretion in the feces. The RCT from macrophages in
atherosclerotic lesions is an important determinant of arterial wall atherosclerotic lesion
formation. Previous studies by our group have shown that treatment with ezetimibe (EZ),
a potent inhibitor of cholesterol absorption from the intestine, results in a 2-6 fold
increase in RCT. To determine whether EZ may increase RCT by mechanisms that are
independent of its well established cholesterol absorption inhibitory effects, we examined
the expression of genes involved in the RCT pathway in the jejunum and liver tissues of
C57BL/6J mice fed a chow diet or chow supplemented with 0.005% EZ. These studies
revealed that treatment with EZ specifically stimulates the expression of Abcg5/Abcg8 in
the liver, but not in the intestine. Further experiments clearly demonstrated that
stimulation of liver Abcg5/Abcg8 expression was due to the inhibition of cholesterol
absorption from the intestine and not a direct effect of EZ in the liver. This conclusion
was further supported by the absence of an ABCG5/ABCG8 expression response to
treatment of primary human hepatocytes with a glucuronated form of EZ. Finally, we
found that the induction of liver Abcg5/Abcg8 accounts for nearly 50% of the EZdependent stimulation of RCT. To our knowledge, our studies are the first to demonstrate
increased liver Abcg5/Abcg8 expression in response to EZ treatment which, in
conjunction with suppression of intestinal cholesterol absorption, synergistically
stimulate the macrophage-to-feces RCT.
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CHAPTER I
INTRODUCTION

Atherosclerosis is a complex chronic inflammatory disease and the underlying cause
of most myocardial and cerebral infarctions (Ross, 1993). The atherosclerotic lesion is
characterized by the accumulation of lipids and inflammatory cells within the arterial
wall, especially by cholesterol laden macrophages. Cholesterol in macrophages is
removed through a process called reverse cholesterol transport (RCT). This process
consists of cholesterol efflux from macrophages to high density lipoproteins (HDL)
which then delivers cholesterol to the liver (Goedeke and Fernandez-Hernando, 2012).
Once in the liver, cholesterol is excreted into bile either as neutral cholesterol or,
alternatively, in the form of bile acids. Biliary sterols that are transported through the
gastrointestinal tract are partly reabsorbed by enterocytes and in part excreted into feces.
The process that transfers cholesterol from macrophages in the arterial wall to the feces is
designated macrophages-to-feces RCT.
Niemann-Pick C1 like 1 (Npc1l1) is localized to the brush border membrane of
enterocytes, and serves as a permease that mediates the uptake of cholesterol from the
intestinal lumen (Xie et al., 2012). Ezetimibe (EZ) is a potent drug that selectively binds
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Npc1l1 and blocks the uptake of cholesterol by enterocytes (Xie et al., 2012). Animal
studies have shown a dramatic 86% decrease in intestinal cholesterol absorption in
C57BL/6J mice treated with 0.005% EZ (Sehayek and Hazen, 2008). Our group was the
first to show that treatment with EZ also increases macrophage-to-feces RCT by 626%
(Sehayek and Hazen, 2008). These observations led us, as well as others, to hypothesize
that EZ increases macrophage-to-feces RCT through decreased intestinal absorption of
macrophage-derived cholesterol that reaches the gastrointestinal tract through biliary
secretion. It should be noted however that this hypothesis has not been carefully
examined. Therefore, we set out to determine whether EZ may increase RCT by
mechanisms that are independent of its well established cholesterol absorption inhibitory
effects. To examine our hypothesis we first investigated the expression of genes involved
in the RCT pathway in the jejunum and liver tissues of chow fed C57BL/6J mice treated
with 0.005% EZ and chow fed controls. These preliminary experiments revealed that EZ
treatment resulted in the induction of the liver neutral sterol hemitransporters Abcg5 and
Abcg8, which are major determinants of liver cholesterol secretion into bile. These
findings were of particular interest, because in mice, Npc1l1, the molecular target of EZ,
is not expressed in liver tissue (Altmann et al., 2004) and raised major questions
regarding the mechanisms whereby EZ stimulates the expression of these
hemitransporters. The main goal of this project was to elucidate the mechanisms whereby
EZ induced liver Abcg5/Abcg8 expression and to determine the role of these
hemitransporters on EZ-dependent stimulation of RCT. To address these questions, we
utilized animals that are targeted for Npc1l1 or Abcg8. From these sets of experiments
we concluded that EZ-dependent stimulation of liver Abcg5/Abcg8 expression is due to
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inhibition of cholesterol absorption from the intestine and that stimulation of these
hemitransporters accounts for nearly 50% of the EZ-dependent increase in RCT.
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CHAPTER II
MATERIALS AND METHODS

Mice Husbandry
Mice were kept at the Cleveland Clinic’s Biological Resource Unit which has a 14/10
light/dark cycle. Animals were bred in-house and pups were weaned at 21 days of age.
Adults were housed in groups of up to 5 mice per cage with ad libitum access to food and
water. Mice were fed either a standard Teklad 2918 chow diet (Harlan Laboratories) or
chow supplemented with 0.005% w/w EZ (Merck Sharp & Dohme Corp.). All
experiments were performed on mice at 14-16 weeks of age. All breeding and
experiments were approved by the Institutional Animal Care and Use Committee.
Npc1l1-KO mice on a C57BL/6J background were obtained courtesy of Yiannis A.
Ioannou at the Mount Sinai School of Medicine in New York (Davies et al., 2005).
Abcg8-KO mice on a C57BL/6J background were obtained courtesy of Shailendra B.
Patel at the Medical College of Wisconsin (Klett et al., 2004).
Mouse Genotyping and PCR
Ear tissue was harvested from pups at 17 days of age and digested overnight in 500 μl
lysis buffer (4 M Urea, 0.5% Sarkosyl, 0.1 M Tris-HCl pH 8, 0.2 M NaCl, 0.01 M EDTA
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pH 8) and 10 mg/ml Fungal Proteinase K (Invitrogen Life Technologies). Digests were
centrifuged at 15,000 rpm for 5 minutes and 450 μl supernatant was mixed with 1 ml
100% ethanol to precipitate the DNA. DNA was spooled, dissolved in 0.1% TE buffer,
and diluted in ddH2O (Gibco Life Technologies) to approximately 30 ng/μl. PCR
reactions were performed using JumpStart Taq DNA Polymerase (Sigma-Aldrich) on
C1000 Thermocycler (Bio-Rad Laboratories). Wild-type, knockout, or heterozygous
genotypes were determined by gel migration of the corresponding wild type and targeted
allele PCR amplicons.
Bone Marrow Macrophage Harvest and Labeling
Twelve days before injection, 5 wild-type mice were euthanized by isoflurane
overdose followed by cervical dislocation. The hind fur was wiped with 100% ethanol
and cut open to expose the hind legs. The muscles around the femurs and the knee joints
were severed, the femoral joints exposed and the femurs removed. Femurs were wiped
clean and kept in ice cold PBS supplemented with 0.5 unit/ml penicillin and 0.5 μg/ml
streptomycin (pen/strep). Femur epicondyles were removed and femurs were placed into
a 0.7 ml centrifuge tube with 100 μl pen/strep supplemented PBS. Femurs were spun for
5 seconds (~6000 rpm), and bone marrow pellets were resuspended and pooled in 10 ml
of pen/strep supplemented PBS. Marrow was centrifuged at 2000 rpm for 5 minutes and
pellet was washed once with an additional 10 ml pen/strep supplemented PBS. Marrow
pellet was resuspended in RPMI medium supplemented with 0.5 unit/ml penicillin, 0.5
μg/ml streptomycin, 0.2 mM glutamine, 50 μM-mercaptoethanol, 10% heat-inactivated
FBS, and 10% L-Cell cultured media (as a source of macrophage stimulating factor).
Cells were grown in 162 cm2 polystyrene flasks at 37°C. Two days before the
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experiment, cells were labeled with RPMI media supplemented with 20 μCi

14

C-

cholesterol (PerkinElmer Inc.), 100 μg/ml of human acetylated LDL, 0.5 unit/ml
penicillin, 0.5 μg/ml streptomycin, and 0.2 mM glutamine. On the day of experiment, the
media was removed, cells were scraped in ice cold PBS and pelleted at 2000 rpm for 5
minutes. Cell pellets were washed twice with ice cold PBS and resuspended in 1.8 ml
DMEM/flask. A triplicate of 25 μl resuspended cell aliquots were counted (on a Packard
1900CA Liquid Scintilation beta counter) for

14

C-label incorporation. Cell suspension

was kept on ice until injected into mice.
Macrophage-to-Feces Reverse Cholesterol Transport
Fourteen days before injection, mice were fed a chow diet or chow supplemented with
0.005% w/w EZ (Merck Sharp & Dohme Corp.). Two days before injection, mice were
transferred and housed individually in conventionally vented cages with wire rack floors.
Mice were weighed, subjected to isoflurane anesthesia, and subcutaneously injected with
300 μl of

14

C-cholesterol labeled bone marrow macrophage suspension. Two days after

injection, feces were collected and dried overnight at 65°C. Dried feces were weighed
and pulverized by mortar and pestle. Sterols in one gram of feces were extracted in 8 ml
of folch organic solvent (2:1 v/v chloroform/methanol) and centrifuged once at 3500 rpm
for 15 minutes at 4°C. A 2 ml sample of the supernatant was mixed with 0.7 ml 0.88%
KCl in a clean glass tube and centrifuged at room temperature for 5 minutes at 3500 rpm.
Next, 1 ml of the organic phase was transferred and evaporated in a scintillation vial at
65°C. After complete evaporation, 4 ml of Ecolite(+) scintillation fluid (MP Biologicals)
was added and 14C-label counted in a Packard 1900CA Liquid Scintilation beta counter.
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Percent total fecal

14

C-label excrete was calculated and expressed as percent of total

DPM in subcutaneously injected bone marrow macrophages.
For neutral sterol extraction, 2 ml of the fecal chloroform/methanol extract was
transferred into a fresh glass tube and evaporated to dryness at 95°C. Sterols were
resuspended in 75% ethanolic solution supplemented with 200 μl 1 N NaOH and
ethanolic hydrolysis was achieved by incubation at 95°C. Neutral sterols were extracted
three times with 2 ml of hexane and centrifuged at 3500 rpm for 5 minutes at 4°C. The
organic phases were pooled and evaporated in a scintillation vial, resuspended in 4 ml of
Ecolite(+) scintillation fluid (MP Biologicals), labeled neutral sterols were counted and
percent neutral fecal

14

C-sterol excretion calculated and expressed as percent of total

fecal 14C-sterol excretion.
For acidic sterol extraction, remaining aqueous phase was evaporated down to
approximately 2 ml (by incubation at 95°C), acidified (by adding 4 ml ddH2O and 800 μl
2 N HCl), acidic sterols extracted three times in 2 ml of ethyl acetate and centrifuged at
3500 rpm for 5 minutes at 4°C. The organic phases were pooled and evaporated in a
scintillation vial, resuspended in 4 ml of Ecolite(+) scintillation fluid (MP Biologicals),
labeled acidic sterols were counted and percent acidic fecal

14

C-sterol excretion

calculated and expressed as percent of total fecal 14C-sterol excretion.
Animal Sacrifice and Tissue Harvest
Animals were fasted for 6 hours and anesthetized with intramuscular injection of
ketamine-xylazine. The peritoneal cavity was exposed and animals were exsanguinated
via a heart puncture. Next the jejunum was cut distal to the Treitz ligament, flushed with
ice cold PBS and stripped of mesentery and fat deposits. A 4 cm segment of the jejunum
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was removed and stored in 1 ml RNAlater solution (Ambion Life Technologies). The
ileum was cut open proximal to the cecum, flashed with ice cold PBS, a 4 centimeter
piece proximal to the ileocecal sphincter was resected and stored in RNAlater solution
(Ambion Life Technologies). Next, the left lobe of the liver was harvested and stored in
RNAlater solution (Ambion Life Technologies). Finally, the right lobe of the liver was
harvested and snapped frozen in liquid nitrogen. All samples were stored at -80°C.
RNA Isolation, Reverse Transcription and qPCR Analysis
Tissue samples were homogenized in 1 ml Trizol reagent (Invitrogen Life
Technologies) by using TissueLyser II (Qiagen), cooled on ice, incubated at room
temperature for 5 minutes and supplemented with 200 μl of chloroform. Samples were
spun at 12000 rpm for 15 minutes at 4°C and the aqueous phase transferred into
isopropanol containing tube, and centrifuged again at 12000 rpm for 10 minutes at 4°C.
RNA pellet was washed in 75% ethanol, centrifuged at 9000 rpm for 5 minutes at 4°C
and resuspended in DEPC treated ddH2O. RNA quality was determined by gel
electrophoresis and 5 μg treated with DNAse (Invitrogen Life Technologies). DNAse
treated RNA was subjected to reverse transcription by incubation with Superscript II
(Invitrogen Life Technologies) and qPCR reactions were performed in triplicate using
SYBR Advantage qPCR premix (Clonetech Labratories Inc.) on a CFX384 Real-Time
PCR platform (Bio-Rad Laboratories). Expression levels were determined by using gene
specific standard curves after normalization to house keeping genes and expression level
of controls. Values were expressed as mean ± SEM. A list of gene specific primers used
can be found in Appendix Table AI.
Liver Cholesterol Analysis by GC-MS
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Approximately 10 mg snap-frozen liver tissue was homogenized in 2 ml ddH2O using
TissueLyser II (Qiagen) and a 15 μl aliquot was transferred into a coprostanol (internal
standard) spiked glass tube, volume completed to 1 ml with ddH2O and mixed with 1.8
ml of solution A (80:20:2 isopropanol:hexane:2 M acetic acid). Lipids were extracted
three times in hexane and centrifuged at 3000 rpm for 10 minutes. The organic phase was
split into two glass tubes and dried under nitrogen (one for total cholesterol and the other
one for free cholesterol determination). For determination of liver total cholesterol
content, one dried tube was resuspended in 100 μl 0.5 M KOH, hydrolyzed at 37°C,
acidified by 1 M HCl and mixed with 900 μl of solution A. Hydrolyzed sterols were
extracted in hexane and organic phase dried under nitrogen. Dried samples were
resuspended in 40 μl Sylon HTP (3:1:9 HMDS:TMCS:Pyridine) (Sigma-Aldrich),
incubated at 90°C for 1 hour, and transferred into airtight GC vials. Finally, 1 μl was
injected into a GC-MS (Agilent Technologies) by following a previously established
protocol (Robinet et al., 2010). GC-MS chromatograms were integrated at m/z = 329 and
370 for cholesterol and coprostanol, respectively, peak areas integrated and liver content
of total and free cholesterol content were expressed as μg cholesterol/ mg liver tissue.
Cholesteryl ester content was determined as the difference between total and free
cholesterol levels.
Primary Human Hepatocytes
Confluent plates of primary human hepatocytes (form a normal 16-year old female
donor) were purchased from Yecuris Corporation (OR). Upon receiving, cells were
incubated with HMM Maintenance Media (Lonza) supplemented with 50 μg/ml
gentamicin sulfate and 50 ng/ml amphotericin-B (Lonza). After 24 hours, media was
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replaced and cells were treated with 0.001% DMSO or 0.001% DMSO plus either 50 μM
chenodeoxycholic acid (CDCA), 30 μM SCH60663 or 120 μM SCH60663 (a
glucuronated metabolite of EZ) (Merck Sharp & Dohme Corp.). After 24 hour
incubation, cells were scraped in Trizol reagent (Invitrogen Life Technologies) and RNA
was processed for cDNA synthesis as described above.
Statistical Analysis
Unless otherwise indicated, group differences were analyzed by using two-tailed
unpaired Students t-test. To pool multiple experiments, raw data were converted into
z-scores (distance from the mean value within an individual experiment in SD).
Throughout this thesis results were expressed as means ± SD unless otherwise indicated.
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CHAPTER III
RESULTS

Ezetimibe upregulates liver Abcg5/Abcg8 expression in C57BL/6J mice
As previously reported, treating C57BL/6J mice with 0.005% ezetimibe (EZ) results
in a dramatic 86% decrease in intestinal cholesterol absorption and a 626% increase in
macrophage-to-feces reverse cholesterol transport (RCT) (Sehayek and Hazen, 2008). To
determine whether EZ may increase RCT by mechanisms that are independent of its well
established cholesterol absorption inhibitory effects, we examined the expression of
genes involved in sterol metabolism (Table I) in the jejunum and liver of chow fed
C57BL/6J mice treated with 0.005% EZ and in chow fed controls. We expected that
treatment with EZ would decrease the delivery of dietary cholesterol from the intestine to
the liver, thereby increasing the expression of Hmgcr, the rate limiting enzyme in the denovo cellular cholesterol biosynthesis pathway in this organ (Goedeke and FernandezHernando, 2012). Indeed, as shown in Figure 1, EZ treated animals displayed a 180%
increase in liver Hmgcr expression levels when compared to chow fed controls.
Moreover, we expected that treatment with EZ will deplete both enterocytes and
hepatocytes of their cholesterol content, thus decreasing the expression of Abcg5 and
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Gene

Full Name
3-hydroxy-3-methylglutarylcoenzyme A reductase

Expression
Liver and
Jejunum

Abcg5

ATP-binding cassette subfamily G member 5

Liver and
Jejunum

Abcg8

ATP-binding cassette subfamily G member 8

Liver and
Jejunum

Hmgcr

ATP-binding cassette subfamily B member 4
ATP-binding cassette subfamily B member 11

Abcb4
Abcb11

Liver
Liver

Cyp7a1

Cholesterol 7 alphahydroxylase

Liver

Fxr

Farnesoid X receptor

Liver

Shp

Small heterodimer partner

Liver

Sr-b1

Scavenger receptor class B

Liver

Npc1l1

Niemann-Pick C1-Like 1

Jejunum

Function
The rate-limiting enzyme in
cholesterol synthesis
Transports neutral sterols
from hepatocytes into bile or
enterocytes into the lumen
Transports neutral sterols
from hepatocytes into bile or
enterocytes into the lumen
Transports phospholipids
from hepatocytes into bile
Transports bile acids from
hepatocytes into bile
The rate-limiting enzyme in
cholesterol to bile acid
synthesis
Transcription factor that
regulates Shp expression
Suppressor of Cyp7a1
expression
Receptor for HDL
Transports cholesterol into
enterocytes

4
3

a

b

Chow
Chow + EZ

b
2

b

Liver
a

b
Npc1l1

Abcg5

Hmgcr

Sr-b1

Shp

Fxr

Cyp7a1

Abcb11

Abcb4

Abcg8

Abcg5

0

b

Abcg8

1

Hmgcr

Relative Expression Level

Table I: Genes involved in sterol metabolism

Jejunum

P<0.02, bP<0.006

Figure 1: EZ specifically stimulates liver Abcg5/Abcg8 expression. Gene expression
in liver and jejunum tissues in chow or chow supplemented with 0.005% EZ fed
C57BL/6J mice, N=5 per group.
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Abcg8, two neutral sterol hemitransporters responsible for the efflux of excess cellular
cholesterol into the intestinal lumen or bile, respectively. Indeed, when compared to
chow fed controls, treatment with EZ resulted in 60% decreased expression of these
hemitransporters in the jejunum (Figure 1). Interestingly however, and contrary to our
expectations, EZ treatment resulted in a 240-300% induction in liver Abcg5/Abcg8
expression (Figure 1). Increased liver cholesterol content has been shown to induce the
liver expression of Abcg5/Abcg8 (Escola-Gil et al., 2011). Considering the induction of
liver Hmgcr, the rate limiting enzyme in de-novo cellular cholesterol biosynthesis, we
examined the liver cholesterol content of EZ treated C57BL/6J mice and controls to
determine if this was the cause. However, we did not find a difference in liver total
cholesterol, free cholesterol, or cholesteryl ester content (Figure 2). Therefore, the
induction of liver Abcg5/Abcg8 raised major questions regarding the mechanisms
whereby EZ stimulates the expression of these hemitransporters, particularly since

g Cholesterol/mg tissue

Npc1l1, the molecular target of EZ, is not expressed in the liver tissue of mice (Altmann

4

Chow
Chow + EZ

3
2
1
0

Total Cholesteryl Free
Cholesterol
Cholesterol Ester

Figure 2: EZ treatment has no effect on liver cholesterol content. Liver total
cholesterol, cholesteryl ester, and free cholesterol content in chow or chow supplemented
with 0.005% EZ fed C57BL/6J mice, N=5 per group.
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et al., 2004). To determine whether EZ-dependent induction of liver Abcg5/Abcg8
expression is due to direct stimulation of these genes in the liver or, alternatively, is
downstream to this drug's effect in the intestine, we turned to study the effect of EZ in
animals that were targeted for the Npc1l1 gene.
Induction of RCT and liver Abcg5/Abcg8 expression is an indirect effect of
ezetimibe
Ezetimibe prevents intestinal cholesterol absorption by selectively blocking
endocytosis of the Npc1l1-cholesterol complex (Xie et al., 2012). Therefore, Npc1l1-KO
mice, which lack this critical permease, are characterized by a 70% decrease in
cholesterol absorption rates (Altmann et al., 2004). For that reason, we utilized Npc1l1KO mice to determine whether increased liver expression of Abcg5/Abcg8 is due to
decreased cholesterol absorption and/or is a direct effect of EZ on Abcg5/Abcg8
expression in the liver.
First, we investigated the effect of decreased cholesterol absorption on RCT. If
induction of RCT was a direct result of decreased cholesterol absorption, we anticipated
that Npc1l1-KO mice will display an increase in RCT like the EZ treated C57BL/6J
mice. Indeed, as shown in Figure 3A, when compared to wild-type (WT) controls, chow
fed Npc1l1-KO mice displayed a 230% increase in RCT. Furthermore, this increase was
entirely attributable to increased fecal neutral radiolabeled sterol excretion (266%) with
no effect on fecal acidic radiolabeled sterol secretion (Figure 3C). These results were
confirmed in a second set of mice and data was pooled via Z-scores to show a highly
significant induction of RCT (Figures 3B and 3D). Our findings indicated that, as
expected, Npc1l1- KO mice displayed an increase in RCT that was similar to what has
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A
8

P<0.04

1

6
4

0
-1

2
0

P<0.0006
2

Z-score

% Total Fecal [ 14C]-sterol
Excretion

B

WT

-2

Npc1l1-KO

D
2
5

P<0.004

Npc1l1-KO

WT
Npc1l1-KO

P<0.04

1

4
WT
Npc1l1-KO

3
2

Z-score

Fecal [14C]-sterol excretion
(% of injected dose)

C

WT

0
-1

1
0

-2
Neutral
[14C]-sterols

Acidic
[14 C]-sterols

Neutral
[14C]-sterols

Acidic
[14 C]-sterols

Figure 3: Npc1l1-KO mice were characterized by increased RCT due to increased
fecal neutral sterol excretion. A) Total RCT, N=5 per group, B) Z-score of total RCT of
two pooled experiments, N=7-10 per group, C) Fecal neutral and acidic 14C-sterols, N=5
per group, D) Z-score of fecal neutral and acidic 14C-sterols of two pooled experiments,
N=7-10 per group.
been observed in EZ treated C57BL/6J mice. Next, we turned to examine the effect of
targeting Npc1l1 on Abcg5/Abcg8 expression in the liver. If EZ increases Abcg5/Abcg8
expression through blocking the absorption of cholesterol, then chow fed Npc1l1-KO
mice should also show increased liver expression of these genes. Indeed, as shown in
Figure 4, Npc1l1-KO mice displayed a gene expression profile that was nearly identical
to EZ treated C57BL/6J mice. Specifically, although stimulation of liver Hmgcr failed to
reach statistical significance, jejunal Hmgcr was significantly induced by 160% (Figure
4). Moreover, jejunal Abcg5/Abcg8 was suppressed by 40-50% and liver Abcg5 and
Abcg8 were induced by 70% and 29%, respectively (Figure 4). Together, these
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WT
Npc1l1-KO
2

a

b
a

1

Liver
a

Abcg8

Abcg5

Hmgcr

Sr-b1

Shp

Fxr

Cyp7a1

Abcb11

Abcb4

Abcg8

0

Abcg5

b
Hmgcr

Relative Expression Level

3

Jejunum

P< 0.03, bP<0.008

Figure 4: Npc1l1-KO mice are characterized by increased liver Abcg5/Abcg8
expression. Gene expression in liver and jejunum tissues of wild-type (WT) and Npc1l1KO mice, N=5 per group.
experiments indicated that, similar to EZ treated C57BL/6J mice, chow fed Npc1l1-KO
mice were characterized by elevated liver expression of Abcg5/Abcg8.
It should be noted however, that these experiments fell short in excluding a direct
effect of EZ on liver Abcg5/Abcg8 expression. To address this possibility we treated
Npc1l1-KO mice with EZ and examined the add-on effect of this drug to RCT and liver
Abcg5/Abcg8 expression. As shown in Figure 5, EZ treated Npc1l1-KO mice displayed
RCT, fecal neutral and acidic radiolabeled sterol secretions that were comparable to the
values seen in controls. These findings were validated in a second experiment and data
was pooled via Z-scores (Figure 5). Most importantly, with the exception of an increase
in jejunal Abcg5, EZ treated Npc1l1-KO mice displayed a gene expression profile that
was indistinguishable from EZ treated wild-type mice (Figure 6). Specifically, EZ treated
Npc1l1-KO mice exhibited liver Hmgcr, Abcg5, and Abcg8 expression levels that were
similar to those seen in their control group (Figure 6). Collectively, these results
unequivocally showed that in Npc1l1-KO mice, EZ treatment had no effect on RCT or
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B
1.5

30

1.0
20

Z-score

% Total Fecal [ 14C]-sterol
Excretion

A

10

0.5
0.0
-0.5
-1.0
-1.5

0

WT

Npc1l1-KO

WT

D

WT
Npc1l1-KO

2
20

WT
Npc1l1-KO

1
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Figure 5: EZ treatment has no effect on RCT in Npc1l1-KO mice. A) Total RCT,
N=5 per group, B) Z-score of total RCT of two pooled experiments, N=9 per group, C)
Fecal neutral and acidic 14C-sterols, N=5 per group, D) Z-score of fecal neutral and acidic
14
C-sterols of two pooled experiments, N=9 per group. WT = wild-type mice.
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Figure 6: EZ treatment has no effect on liver Abcg5/Abcg8 expression in Npc1l1-KO
mice. Gene expression in liver and jejunum tissues of EZ treated wild-type (WT) and
Npc1l1-KO mice, N=5 per group.
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liver expression of Abcg5/Abcg8.
This set of experiments strongly suggested that EZ-dependent stimulation of RCT and
liver expression of Abcg5/Abcg8 is due to inhibition of cholesterol absorption from the
intestine. It should be mentioned however, that the above-described experiments were
done in-vivo and may mask potential direct EZ effects on liver Abcg5/Abcg8 expression.
To ascertain the absence of a direct EZ effect on liver Abcg5/Abcg8 expression we
turned to examine the effect of this drug on ABCG5/ABCG8 in human primary
hepatocytes.
Ezetimibe metabolite has no effect on Abcg5/Abcg8 expression in primary human
hepatocytes
Primary human hepatocytes (PHH) express NPC1L1, ABCG5, and ABCG8, making
them an ideal in-vitro model to test the indirect effect of EZ. Ezetimibe is largely
glucuronated in the small intestine and its glucuronated metabolites reach the liver
through the portal system (Phan et al., 2012). Therefore, to examine the effect of EZ on
gene expression in PHH we used a glucuronated form of EZ, SCH60663. In these
experiments, chenodeoxycholic acid (CDCA), a major bile acid in human bile, served as
a positive control. CDCA is a well established stimulator of small heterodimer partner
(SHP), a liver transcription inhibitor that regulates key enzymes and transporters in bile
acid metabolism. Indeed, and as shown in Figure 7, when compared to DMSO treated
cells, PHH treated with 50 µM CDCA displayed a 395% increase in SHP expression.
These findings clearly indicated that our primary human hepatocytes were an appropriate
model for in-vitro sterol metabolic studies. Our findings in Npc1l1-KO mice strongly
suggested that EZ indirectly effected Abcg5/Abcg8 expression through the inhibition of
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Figure 7: SCH60663 treatment of primary human hepatocytes has no effect on
ABCG5/ABCG8 expression. Gene expression in primary human hepatocytes treated
with 0.001 % DMSO supplemented with 30 μM and 120 μM SCH60663, or 50 μM
CDCA, N=3 per group.
cholesterol absorption from the intestine. Based on these findings we expected that
incubating PHH with SCH60663 will have no effect on ABCG5/ABCG8 expression.
Indeed, as shown in Figure 7, treating PHH with incremental doses of SCH60663 (which
correspond to concentrations measured in EZ treated patients) displayed no effect on
ABCG5/ABCG8 expression. Interestingly, CDCA treatment induced ABCG5/ABCG8
expression by 247-358% (Figure 7). However, further investigation into CDCA-induced
increase of ABCG5/ABCG8 was outside the scope of this study. This set of experiments
clearly excluded a direct effect for this drug on liver expression of these genes and
indicated that in C57BL/6J mice, the stimulation of Abcg5/Abcg8 is downstream to the
effect of EZ on cholesterol absorption.
Liver Abcg5/Abcg8 expression accounts for 50% of the ezetimibe induced RCT
effect
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To determine the role of liver Abcg5/Abcg8 on EZ-dependent stimulation of RCT, we
examined the effect of EZ in mice targeted for the Abcg8 gene. Liver Abcg5/Abcg8
hemitransporters are responsible for the efflux of cholesterol from hepatocytes into bile
and Abcg8-KO mice are characterized by largely decreased biliary cholesterol secretion
(Klett et al., 2004). Therefore, we utilized Abcg8-KO mice to determine whether the EZdependent stimulation of RCT is, at least in part, attributable to increased biliary
cholesterol secretion into bile.
First, we examined whether targeting of Abcg8 has an effect on RCT. As shown in
Figure 8A, chow fed Abcg8-KO mice displayed RCT levels that were similar to those in
controls. Interestingly, however, Abcg8-KO mice were characterized by a shifted balance
in fecal sterol secretion, as reflected by a 56% decrease and 50% increase in fecal neutral
and fecal acidic radiolabeled sterol secretion respectively (Figure 8B). We also examined
the gene expression profile in chow fed Abcg8-KO mice. Consistent with previous
reports (Klett et al., 2004) and as seen in Figure 9, chow fed Abcg8-KO mice had a 45%
decrease in liver Hmgcr expression and liver Abcg5 expression was below our qPCR
detection limit. In addition, when compared to their controls, Abcg8-KO mice displayed
Fecal [14C]-sterol excretion
(% of injected dose)
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Figure 8: Abcg8-KO mice display RCT that was indistinguishable from controls,
but opposing neutral and acidic fecal 14C-sterol excretion. A) Total RCT, N=5 per
group, B) Fecal neutral and acidic 14C-sterols, N=5 per group. WT= wild-type mice.
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a 38% decrease in liver Farnesoid X receptor (Fxr) expression, a bile acid receptor that
regulates the transcription of critical genes in bile acid metabolism (Figure 9). However,
studies into mechanisms that modify Fxr suppression in Abcg8-KO mice are beyond the
scope of this project. From this series of studies we concluded that targeting of Abcg8
had no overall effect on RCT.
Next, we addressed the effect of EZ in Abcg8-KO mice. We expected that, in Abcg8KO mice, EZ treatment would not be able to induce RCT to the same extent as in wild
type animals. Indeed, as shown in Figure 10A, when compared to their controls, EZ
treated Abcg8-KO mice displayed a 50% decrease in RCT. Furthermore, this decrease
was largely attributable to a 38% decrease in fecal neutral radiolabeled sterol secretion
(Figure 10C). This observation was confirmed in a second set of mice and pooling of data
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after conversion into Z-scores showed a highly significant reduction in RCT (Figures 10B

Jejunum

b

P<0.01, P<0.003

Figure 9: Abcg8-KO mice display decreased expression of liver Hmgcr, Abcg5, and
Fxr. Gene expression in liver and jejunum tissues of wild-type (WT) and Abcg8-KO
mice, N=5 per group.
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and 10D). Finally, we examined the gene expression profile in EZ treated Abcg8-KO
mice. Unexpectedly, EZ treatment in Abcg8-KO mice induced the expression of liver
Abcb4, the biliary phospholipid transporter, by 34% and the expression of Shp by 233%
(Figure 11). Further studies are needed to clarify the mechanisms whereby EZ induces
the expression of Abcb4 and Shp in Abcg8-KO mice. However, these studies are beyond
the scope of this project. Taken together, our experiments showed that increased
Abcg5/Abcg8 expression accounts for nearly 50% of EZ-dependent increase in RCT.
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Figure 10: EZ treated Abcg8-KO mice are characterized by decreased RCT due to
suppressed fecal neutral sterol excretion. A) Total RCT, N=5 per group, B) Z-score
of total RCT of two pooled experiments, N=8-9 per group, C) Fecal excretion of neutral
and acidic 14C-sterols, N=5 per group, D) Z-score of fecal neutral and acidic 14C-sterols
of two pooled experiments, N=8-9 per group. WT = wild-type mice.
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Figure 11: EZ treatment stimulates liver Abcb4 and Shp expression in Abcg8-KO
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Abcg8-KO mice, N=5 per group.
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CHAPTER IV
DISCUSSION

Our studies showed that treatment with EZ specifically stimulates the expression of
Abcg5/Abcg8 in the liver, but not in the intestine (Figure 1). Our experiments in Npc1l1KO mice clearly demonstrated that stimulation of liver Abcg5/Abcg8 expression is due to
the inhibition of cholesterol absorption from the intestine and not a direct effect of EZ in
the liver (Figures 4 and 6). This conclusion is supported by the absence of an
ABCG5/ABCG8 response to the glucuronated form of EZ in primary human hepatocytes
(Figure 7). Finally, we found the up-regulation of Abcg5/Abcg8 accounts for nearly 50%
of the EZ-dependent stimulation of RCT in response to EZ treatment (Figure 10).
Our studies showed for the first time that, in the mouse, decreased intestinal
cholesterol absorption due to either EZ treatment or deletion of its molecular target,
Npc1l1, stimulates the expression of Abcg5/Abcg8 in the liver, but not in the intestine
(Figures 1 and 4). The expression of Abcg5/Abcg8 in the mouse is regulated by three
distinct transcriptional factors: Liver X receptor alpha (Lxrα), Forkhead box O1 (Foxo1),
and Hepatocyte nuclear factor 4 alpha (Hnf-4α) (Brown and Yu, 2010). Probably the
best-studied regulator of Abcg5/Abcg8 expression is Lxrα, a sterol-sensing transcription
factor that is activated by hydroxylated forms of cholesterol, designated oxysterols. Since
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liver cholesterol is the precursor of oxysterols, increased liver sterol content in response
to high cholesterol feeding results in Lxrα activation and increased Abcg5/Abcg8
expression (Repa et al., 2002). Interestingly, we found that treatment with EZ in animals
fed a chow diet, which is a poor source of cholesterol (0.02% w/w), stimulated the
expression of Abcg5/Abcg8 in the liver. Moreover, our studies found no change in liver
cholesterol content in chow fed controls and EZ treated C57BL/6J mice (Figure 2). It is
therefore conceivable that treatment of chow fed animals with EZ results in a small, but
critical, depletion in the liver regulatory cholesterol pool which controls Abcg5/Abcg8
expression, a depletion that cannot be detected by our GC-MS method. An unambiguous
indication for such depletion is provided by the stimulation of Hmgcr expression, the rate
limiting enzyme in de-novo cellular cholesterol biosynthesis (Figure 1). Therefore, in
addition to conditions where liver cholesterol content is increased, our findings indicate,
for the first time, that expression of liver Abcg5/Abcg8 is inducible under conditions
where the regulatory cholesterol pool is depleted. These findings raise an intriguing
question: what is the mechanism whereby depletion of liver cholesterol content increases
the expression of Abcg5/Abcg8? Brown and Goldstein have shown that endoplasmic
reticulum-bound sterol regulatory element-binding protein 2 (Srebp-2) is responsible for
orchestrating the transcriptional regulation of genes under conditions where the cellular
cholesterol regulatory pool is depleted (Sheng et al., 1995). It is therefore conceivable
that Srebp-2 is responsible for activation of Abcg5/Abcg8 in EZ treated animals. Indeed,
studies in animals targeted for Srebp cleavage-activating protein (Scap), a cholesterol
sensing protein which resides and tethers the inactive Srebp-2 to the endoplasmic
reticulum, indicated that Srebp-2 is responsible for stimulation of Abcg5 expression in
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the liver (Horton et al., 2003). It is of note that in our studies, stimulation of Abcg5 was
consistently higher than the corresponding stimulation of its Abcg8 partner. Interestingly,
other studies have demonstrated that Srebp-2 can positively interact with Hnf-4α
(Misawa et al., 2003), a known transcription factor for Abcg5/Abcg8 expression. A
definitive

link

between

Abcg5/Abcg8,

Hnf-4α,

and

Srebp-2

needs

further

experimentation that is beyond the scope of this thesis.
Reverse cholesterol transport consists of the transfer of cholesterol from peripheral
tissues for ultimate excretion in the feces. However, the pathways involved are not fully
understood. The classical view of the RCT process holds that cholesterol from peripheral
tissues is transferred to the liver, excreted into bile, reaches the intestine and, ultimately is
eliminated in the feces. This view has been recently challenged by observations that
suggested a bypass of the biliary tract and direct excretion of cholesterol into the
intestine. This process has been designated transintestinal cholesterol excretion or in short
TICE (Temel et al., 2010, Temel and Brown, 2012). Our studies strongly support the
importance of biliary excretion in determining the RCT process. Our experiments in
Abcg8-KO mice strongly indicate that absence of liver Abcg5/Abcg8 induction in
response to EZ treatment results in a 50% decrease in RCT (Figure 10). While our
macrophage-to-feces RCT studies cannot exclude TICE as a potential mechanism, the
induction of liver, but not intestinal Abcg5/Abcg8 strongly suggests that, in EZ treated
animals, increased fecal secretion of neutral radiolabeled sterols is biliary-dependent.
Therefore, our studies indicate that biliary cholesterol secretion is an important
determinant of RCT. It should be noted, however, that our studies couldn’t absolutely
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exclude a role for TICE. A definitive answer awaits elucidation of the molecular basis of
the TICE pathway.
To our knowledge, our studies are the first to demonstrate increased liver Abcg5/Abcg8
expression in response to EZ treatment and, in conjunction with suppression of intestinal
cholesterol absorption, synergistically stimulate macrophage-to-feces RCT. Our findings
highlight the role of liver Abcg5/Abcg8 in determining the RCT process. The exact
mechanisms whereby depletion of liver cholesterol content increase the expression of
Abcg5/Abcg8 and clarification of the balance between biliary cholesterol secretion and
TICE in determining the RCT response to EZ needs further experimentation.
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APPENDIX
Primer

Forward Sequence

Reverse Sequence

hABCG5
hABCG8_RT
hBACTIN
hNPC1L1
hSHP
mAbcb11
mAbcb4
mAbcg5
mAbcg8
mBactin
mCyp7a1
mFxr
mHmgcr
mNpc1l1
mPabpc1
mShp
mSr-b1

CGTTCTGCGGGTCCGAAGCA
TTCCTGCTGGTGTGGCTGGTGGTC
CCCCCATGCCATCCTGCGTCTG
GCCTCCAGGTTCATGGCCTATCACA
CTCACGGCCTCCACCCTCAAGTCC
CAGGGAGGCCAAAGGTGAGC
CCGCTATGGCCGTGGGAATGTAA
CTGCTGAGGCGAGTAACAAGAAAC
GTACGTGGGGTGTCCGGGGGTGAG
GGCACCACACCTTCTACAATG
TGCCTTCTGCTACCGAGTGATGTT
TTGTGCCGGAAGGGATGAGTGTG
GAGGCCCAGTGGTGCGTCTTCC
AGTGCGGTGTTTGCTGGAGTGG
AGCCATGCACCCTTCTCTTG
AGCGCTGCCTGGAGTCTTTCTG
ATGGGCCAGCGTGCTTTTATGAAC

AGCTCGCAGCACGGGAAACAG
CCCCCGGCGAGGTAGAAGGAGTTG
CTGGGCCGTGGTGGTGAAGC
GGCACTTTCCGCAGGTCAGCA
GTCCCCAAGAAGGCCAGCGATGTC
ATGGTGGCAGGGAATGAAAAGTAG
ACTCAGCTGCGCCCCTCTATCACC
GACGCGGAGAAGGTAGAAAATGAG
GCGAGGCTGGTGGAGGGAGATGAG
GGGGTGTTGAAGGTCTCAAAC
CGGGCTTTATGTGCGGTCTTGA
TCCGGTTGTTGGGGGTAGAAGC
GGTTGCGTCCTGCCATCGTCAC
AGGAGGTTGAGGCGGAAGAAGAAA
AGTTGGAACAACAGTGGCAC
ACGGAGGCCTGGCACATCTG
ACGCCCGTGAAGACAGTGAAGACC

Table AI: Primers used for gene expression studies
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